Untitled

Abstract

Telmisartan has a strong, nonpeptide antagonist with long-acting angiotensin II type-1 (AT 1) receptor to treat essential hypertension. It is classified as a BCS class II medication, meaning it has poor solubility and high permeability. Because of their capacity to minimise toxicity and change bioavailability, niosomes are becoming increasingly essential in medication delivery. Telmisartan-loaded niosomes were created by adjusting the span 60 and cholesterol ratios in a thin film hydration technique and then assessed for vesicles size, entrapment efficiency and drug release. Batch N6 fulfilled all the requirements and hence it was selected as an optimized formulation of noisome. This investigation supports the use as carriers for developed niosomes to enhance the administration of Telmisartan by oral route. INTRODUCTION:Niosomes are non-ionic surfactant-based multilamellar or unilamellar vesicles in which an aqueous solution is completely encased by a membrane formed by surfactant macromolecules organised as bilayers. Niosomes are microscopic structures with lamellar features. The niosomes are cholesterol and a non-ionic surfactant of the alkyl or dialkyl polyglycerol ether type that is hydrated into an aq. media. To form a bilayer, the surfactant molecules align themselves such that their hydrophilic ends face each other. Although physically identical to liposomes, they are a better option to liposomes in drug delivery systems due to their increased stability. Niosomes serve as therapeutic reservoirs, allowing drugs to be QUICK RESPONSE CODE